Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais an oral anti-cancer star targeting FGFR mutations, which has a significant inhibitory effect on tumors such as urothelial carcinoma, but it has not yet landed in the dom···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：224
Balversa is an oral anticancer drug that specializes in FGFR mutant tumors, such as urothelial carcinoma, and effectively inhibits tumor proliferation, but has not yet been introdu···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：228
Balversa is an oral anticancer drug used for the treatment of locally advanced or metastatic urothelial carcinoma, inhibiting FGFR activity to stop tumor growth, but it is not curr···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：186
Accurately understanding the dosage of Balversa is the key to achieving the best treatment results. Below, let's discuss the dosage of Balversa in detail.What is the dosage of ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：163
Mastering the correct use of Balversais the first step to ensuring efficacy and safety, so let's dive into its detailed medication guidelines.How to use BalversaThe use of Balv···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：180
In-depth analysis of the treatment of Balversa, the primary concern is its recommended dose, which is directly related to the safety and effect of treatment.What is the recommended···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：245
Alpelisib effectively treats patients with HR/HER2- breast cancer harboring PIK3CA mutations by inhibiting the PI3Kα signaling pathway; The precise targeting effect greatly reduces···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：247
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the treatment of HR/HER2- breast cancer. By targeting PIK3CA mutations, drugs can prolong the progression-···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：261
Alpelisib, approved in 2019, has a unique efficacy against PIK3CA mutant breast cancer. Alpelisib has become a key drug for the treatment of advanced breast cancer by blocking the ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：203
Alpelisib is the first PI3K inhibitor specifically for PIK3CA-mutated breast cancer and can be used in combination with fulvestrant to significantly prolong progression-free surviv···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：179
Alpelisib was approved by the FDA in 2019 for the treatment of breast cancer patients with HR/HER2- and PIK3CA mutations. By inhibiting the PI3K signaling pathway, Alpelisib effect···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：205
Alpelisib is the first PI3Kα inhibitor to be used in combination with fulvestrant for the treatment of HR/HER2- breast cancer. By targeting the PIK3CA mutation, Alpelisib significa···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：262
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3172024-09-07
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：122025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：232025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：272025-27-11
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：3062025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：2712025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：3502024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：2492024-24-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
